

## URINARY SUPPORT

*GRAMINEX Flower Pollen Extract*

# Flower Pollen Extract and its Effects on Urinary Support, Bladder and Smooth Muscle

---

### Contents

A Critical Review of Cernitin for Symptomatic Relief Of Lower Urinary Tract Symptoms (LUTS) in Men .....	2
Effects of Pollen-Extract Components, Diamines and Derivatives of Feruloylputrescine on Isolated Bladder and Urethral Smooth Muscles of Mice.....	11
Effect of Cernitin pollen-extract (Cernilton®) on the Function of Urinary Bladder in Conscious Rats .....	12
A Critical Review of Graminex Flower pollen extract for Symptomatic Relief Of Lower Urinary Tract Symptoms (LUTS) in Men .....	13

## A Critical Review of Cernitin for Symptomatic Relief Of Lower Urinary Tract Symptoms (LUTS) in Men

Harry G. Preuss<sup>1</sup>  
Debasis Bagchi<sup>2</sup>  
Walter G. Chambliss<sup>3</sup>

<sup>1</sup> Department of Physiology and Biophysics, Georgetown University Medical Center, Washington, D.C. USA

<sup>2</sup> Department of Pharmacy Sciences, School of Pharmacy and Health Professions, Creighton University Medical Center, Omaha, NE. USA

<sup>3</sup> National Center for Natural Products Research, and Department of Pharmaceutics, University of Mississippi, Research Institute of Pharmaceutical Sciences, School of Pharmacy, University, MS. USA

### Objective

We reviewed published data concerning the ability of a defined flower pollen extract derived from rye, corn, and timothy, commonly referred to as Cernitin to provide symptomatic relief in men suffering from lower urinary tract symptoms (LUTS). This same defined pollen extract has also been called Cernilton in other reports and is commercially available as Graminex Flower Pollen Extract. To maintain clarity, however, we will only use the term Cernitin to describe the defined pollen extract. In writing this review, our major goal is to present evidence concerning the therapeutic role of Cernitin in the management of mild to moderate LUTS. Nevertheless, we briefly describe prostatic perturbations in general and other natural therapeutic approaches to alleviate symptoms caused by them.

### Introduction

It is estimated that 9-10 million men have lower urinary tract symptoms (LUTS) secondary to an enlarged prostate; and 400,000 surgeries are conducted each year in the U.S to alleviate such symptoms [1,2]. Although cancer might be a root cause, LUTS are more commonly found in men with non-cancerous conditions such as benign prostate hyperplasia (BPH), prostatic dysplasia, acute and chronic prostatitis caused by a bacterial infection, as well as chronic non-bacterial prostatitis. BPH, the most common cause of LUTS, does not distinguish between race and ethnic background, although African-American men are at a slightly greater risk [3]. It does not relate to sexual activity, since it can occur in celibate priests as well as the most sexually active of men [4]. Regardless of the etiology of the specific prostate-related disorders, health worries

associated with prostatic enlargement are significant. Over \$1 billion dollars are spent each year on treatment for prostatic enlargement, because LUTS can lead to more serious health problems if not treated properly [5].

The term LUTS describes men experiencing one or more symptoms listed on the International Prostate Symptom Score (IPSS) questionnaire. Among the mentioned urinary symptoms are daytime and night time (nocturia) frequency, urgency, hesitancy, intermittency, sensation of incomplete voiding, and decreased force of urinary stream [2]. An individual often becomes aware of the problem when urination occurs more frequently than usual. He may eventually become the person who rarely can sit through a movie or concert -- the one that requests the aisle seat on an airplane so as not to disturb his fellow passengers on his frequent sojourns to the

restroom. At night, the trips to the bathroom caused by nocturia steadily increase, and there is a definite impingement on sleep. Suffice it to say, any experiencing of such frequency should lead to suspicion of the disorder.

What do we know about this troublesome gland? The prostate gland is associated with the male reproductive system. Its major function is to produce and discharge a viscous, alkaline liquid that provides a major portion of the seminal fluid. The prostate makes and stores fluid almost continuously. Because of the environment afforded by the presence of prostatic fluid, sperms are protected, at least to some extent, and can survive longer after ejaculation. In addition, the prostatic fluid contains prostaglandins, which are fatty acids that, similar to hormones, affect smooth muscle fibers and blood vessel walls. Although the prostate plays no direct role in the functioning of the male urinary system, its location near the bladder and urethra cause many urinary perturbations when it expands via growth or response to chronic inflammation [6-8].

At birth, the gland is the size of a pea and grows slowly until puberty. Under the influence of sex hormones, the prostate grows at a faster pace. During the 20's and 30's, the gland is characteristically the size of a walnut and weighs roughly one ounce. The gland, made up of muscular and glandular tissue, is located in front of the rectum and below the urinary bladder. Importantly, the gland surrounds the urethra, a tube that carries urine from the bladder to the tip of the penis for expulsion. Obviously, this setting has the potential to cause problems and unfortunately does. Around the age of 45, cells in the majority of prostates began to multiply again and the gland can reach up to 10 times the normal adult size [3].

The prostate can be divided into various lobes, with the major problems of BPH lying in the small transitional zone. The transitional zone that lies within the so-called middle lobe is the sole site of BPH [9]. Interestingly, the small transition zone comprises only two per cent of the entire prostatic mass before enlargement. Obviously, enlargement of this area does not in itself increase the size of the prostate greatly. Because of this, the degree of urethral obstruction may not directly relate to the overall size of the prostate gland but instead to the direction of growth enlargement. Some men with greatly enlarged prostates may have no signs of obstruction, while those with relatively small prostates may have severe obstruction.

While the exact mechanism behind age-related enlargement of the prostate is uncertain, a highly active form of the male hormone, testosterone, called dihydrotestosterone (DHT), is considered a major factor behind prostatic enlargement [4]. Excessive levels of DHT have been found in men with enlarged

glands, and high concentrations of DHT are also associated with an increased risk of prostate cancer. To make matters worse, the concentration of DHT within the prostate increases with age. A major factor in the rise is that the enzyme responsible for the conversion of testosterone to DHT, 5-alpha reductase, becomes more active over the lifespan. Therefore, it is not too surprising that 5-alpha reductase is an important focal point in the medical treatment of prostate enlargement. Nevertheless, it is equally important to be aware that other prostatic enzymes, such as 3 oxidoreductase, deficiency of minerals such as zinc, and inflammation may also play a role in the enlargement process.

### Background of Treatment

Bruskewitz points out that since serious complications from BPH and related non-cancerous conditions are rare, the primary aim of pharmacological treatment is to improve quality of life by relieving the vexing symptoms [10]. Studies conducted in the U.S. showed that urologists provided no specific treatment 77% of the time to men with mild symptoms. With moderate symptoms, however, prescription drugs were given 89% of the time; and surgery was conducted 1% of the time. The primary therapeutic treatment was use of alpha (1)-adrenoceptor antagonists such as terazosin hydrochloride (Hytrin®) that provide symptomatic relief but have not been shown to influence the incidence of surgery, acute urinary obstruction, or other complications of BPH [11]. In the past, treatment options for significant prostate enlargement focused on surgery. In a given year, approximately 400,000 men are driven to undergo a procedure called a transurethral resection of the prostate (TURP). Even now, transurethral resection is the standard treatment for BPH, i.e., the gold standard by which all other procedures are measured [12]. Unfortunately, while many symptoms of obstruction are ameliorated, post urination dripping may continue and may even result in severe incontinence. Even worse, the operation may be followed by a decline in sexual function. This may also occur with the use of the common pharmaceuticals as well [2]. Accordingly, a need exists for safe, effective products that can be used to treat mild to moderate LUTS in lieu of or in addition to prescription drugs and major surgery. Natural products have been considered among the alternative therapies.

### Natural Products to Treat LUTS

*Saw Palmetto (Serenoa Repens)*  
Research carried out in Europe over the past 20 years shows that natural, fat-soluble extracts from specific plants effectively inhibit the function of 5-alpha-reductase, and block, at least in part, the formation of DHT [13-16]. The best-known and most

extensively researched plant is saw palmetto. Saw palmetto is an extract of the pulp and seeds of a dwarf, scrubby palm tree native to the West Indies and the Atlantic coast of the United States. Saw palmetto works, for the most part, by the same mechanism as the pharmaceutical Proscar®, i.e., preventing the conversion of testosterone to DHT [16]. Additional benefits from plant extracts have also been found and may add to the good results found with their use. Some plant extracts not only lower the rate of DHT formation, but also block the ability of DHT to bind to cells, preventing the action of hormone [17,18]. In addition, they may prevent severe inflammatory responses. Saw palmetto, known to be popular in Europe, has recently become recognized in America. In one study using saw palmetto in 110 men, it decreased nighttime urination by 45 percent, increased urinary flow rate more than fifty percent, and reduced the amount of urine left in the bladder after urination by 42 per cent [19]. In other large trials, improvement in prostatic symptomatology was readily noted and saw palmetto even compared favorable with Hytrin and Proscar when they were compared head to head [20-24].

#### *Pygeum*

The powdered bark of the pygeum tree, a large tropical African evergreen, has been used for centuries to treat urinary disorders [25]. Pygeum contains phytoosterols, which have been purported to have anti-inflammatory properties. In addition, much benefit has been attributed to their ability to decrease prostatic swelling, to reduce harmful prostaglandins that induce inflammation, and to diminish circulating prolactin that decreases the prostate uptake of testosterone. When 263 German men were tested with *Pygeum africanum*, urinary symptoms improved in 66% compared to 31% in the placebo group [26]. Occasional gastrointestinal upset seems to be the major adverse side effect.

#### *Africanum*

#### *Stinging Nettle (Urtica dioica)*

Less research has been performed using the stinging nettle to ameliorate BPH. Laboratory studies have shown its ability to inhibit laboratory induced prostate growth in mice [27]. The results from one study suggest that the steroidal components of stinging nettle roots suppressed prostate cell growth [28].

#### *Beta-sitosterol*

Much attention has recently been focused on beta-sitosterol. In a randomized double blind study reported in the Lancet, 200 patients from eight private urological practices were treated for six months with either 20 mg of beta-sitosterol or placebo [29]. At the end of six months, modified Boyarsky scores decreased statistically in the beta-sitosterol treated group compared to placebo. The quality of life score improved, the peak urine flow increased, the mean voiding time and the urinary volume retention also improved from the initial scores in the verum group,

whereas no changes were noted in the placebo group. Results were also positive in another randomized, double-blind and placebo-controlled study carried out in Germany [30].

#### *Cernitin*

Cernitin is a natural product recently introduced in the USA to be used to treat LUTS. However, it has actually been around a long time. In 1950, in a tiny Swedish village, a beekeeper found a way to collect pollen artificially [31]. Since it was good for bees, his hypothesis was that it would be good for humans. Initially, the flower pollen was used as a prophylactic agent against infections. Later the extraction process was modified so that the active pollen was released and was non allergenic. Found in the pollen are peptides, carbohydrates, fatty acids, vitamins, minerals, nucleic acids, and enzymes. Whatever the original hypothesis concerning overall health, the defined pollen extract called "Cernitin" proved specifically useful in treating BPH and other prostate conditions [2,32].

Cernitin is a standardized extract of rye pollen (*Secale cereale*), corn pollen (*Zea mays*), and timothy pollen (*Phleum pratense*). From these combined pollens, two important, therapeutic extracts are derived -- a water-soluble fraction and a lipid-soluble fraction with different physiological functions. *In vitro* and *in vivo* animal studies [33,34] have shown that both fractions have anti-inflammatory properties emanating from inhibition of prostaglandin and leukotriene synthesis. The water-soluble fraction has been shown to reduce the size of the ventral and dorsal prostate in the rat [35] and to inhibit testosterone-induced BPH in castrated animals [8]. The combined extracts were shown to inhibit growth of transplanted human BPH tissue in an athymic nude mouse model (36). Both fractions have been shown to relax the smooth muscle of the mouse and pig urethra, increase bladder muscle contractions [34], and reduce prostate size in mature Wistar rats [37].

Cernitin extracts are also sold as Graminex Flower Pollen Extract and are available in the marketplace in tablet and capsule forms, usually contain 63 mg of a 20:1 ratio of water-soluble to lipid-soluble fractions. Cernitin is contained in products regulated as drugs in Switzerland, Germany, Austria, Japan, South Korea and South Africa. In the U.S., the use of botanicals for LUTS is relatively less. No botanicals are approved as prescription or over-the-counter drugs for LUTS or BPH in the U.S. Accordingly, they are sold as dietary supplements and are labeled with non-specific information, e.g., "maintains prostate health." In a study conducted in Chicago in 1997-1998 with 738 men having LUTS and/or prostate disease, Bales et al [38] found that 13% of the group had used botanicals for their condition (59% in combination with prescription drugs), 37% were aware of botanicals as an option but had never used them, and 50% were

unaware of this treatment option. Such information prompted our review of Cernitin.

## Methods

Literature searches were conducted on Medline and the Cochrane Library. Sources such as review articles and monographs in botanical reference books and other books referring to Cernitin were included in the analysis. Open label and comparative trials were included in the assessment, although more weight was given to placebo-controlled, double-blind studies. Emphasis was placed on subject ratings of symptoms in light of the potential for self-medication of this extract.

## Results

### *Reviews, Books, and Monographs*

Four reviews [39-43] and a number of books/monographs [2,44-46] dealing largely with the clinical efficacy and safety of Cernitin have been published in recent years. Each used its own criteria to select studies considered to be valid. Because all reviews concluded that Cernitin is very safe with few or no side effects, the summaries described below are essentially limited to efficacy.

In the first, Commission E, an expert committee established by the German government to evaluate the safety and efficacy of over 300 botanical and botanical combinations sold in Germany, concluded in 1994 that combining extracts of rye, corn, and timothy pollen was useful in the treatment of "micturition difficulties associated with Alken stage I-II benign prostatic enlargement (BPH)" [39]. In the second, the Natural Medicines Comprehensive Database concluded that rye grass pollen extract (Cernitin) was "possibly effective" for the management of BPH symptoms, for shrinking prostate size, and for prostatitis and prostatic dysuria based on the information it gathered [40]. In the third source, the same group published reviews in 1999 and 2000 based upon results from 4 double-blind studies (444 men in total, 2 studies with placebo; 2 with active controls) [41,42]. Results consistently showed a "modest" improvement in subjective symptoms and nocturia in the Cernitin groups compared to placebo, Paraprost (a mixture of the amino acids L-glutamic acid, L-alanine, glycine) and Tadenan (Pygeum africanum extract). The authors called for additional studies to evaluate long-term effects. In the final review, Shoskes concluded that there was credible clinical and scientific evidence that treatment with Cernitin pollen extract was efficacious for the majority of patients with non-bacterial prostatitis and prostatic dysuria [43]. The books/monographs largely corroborate the conclusions of the reviews [2,44-46].

### *Research*

Again, Cernitin was well tolerated in all of the

### *Papers*

published studies from primary literature with minimal reported side effects. Therefore, the discussion will continue to focus on efficacy.

In the 1960's, Leander [47] published results of a carefully controlled trial. He compared placebo with Cernitin pollen extract in 179 cases. Using pollen extract, Leander found a 60-80 per cent improvement over placebo in symptoms of obstruction, probably through elimination of inflammatory edema. Around the same time, much work was progressing in Japan. Inada et al [48] reported favorable effects in 12 patients suffering from prostatic hypertrophy. They reported that five cases had "effective" results; five showed "slightly effective" results and two reported "ineffective" results. In 1967, Ohkoshi, Kawamura and Nagakubo of Keio University, reported impressive results in 30 patients with prostatitis and/or urethritis [49]. Examining 14 patients receiving Cernitin, it was found that treatment was "successful" in 10, "slightly effective" in three, and "ineffective" in only one case. In 16 patients given placebo, seven found the treatment to be "effective" and nine reported "no change."

In 1981, Takeuchi [50] investigated both subjective and objective effects of Cernitin on 25 men with BPH. The efficiency rate for Cernitin was reported as 64%. There was a 50% improvement for nocturnal micturition. Horii et al [51] reported the results of 30 subjects with BPH who were given Cernitin 2 tablets, 3 times daily for at least 12 weeks. The overall clinical efficacy for subjective symptoms was rated at 80% and objective symptoms at 43%. Ueda et al [52] treated 22 patients with stage I and II BPH with Cernitin for over 4 weeks. Eighty-two percent of the patients were rated as moderately improved or better. Hayashi et al [53] treated 20 BPH patients with Cernitin, 6 tablets a day for an average of 13.2 weeks. They reported improvements in sense of residual urine (92%), retardation (86%), night frequency (85%), strain on urination (56%), protraction (53%), and forceless urinary stream (53%). Overall subjective effectiveness was 80% and overall objective effectiveness was 54%.

In 1986, a field study of 2,289 patients being treated by 170 urologists was undertaken [54]. They examined the effectiveness of Cernitin pollen extracts on chronic prostatitis and/or BPH. Improvement of symptoms was reported in 64 to 82%, in contrast to a low rate of adverse reaction found only in 2.9% of cases. In the same year [55], Brauer compared the effects of Cernitin and beta-sitosterol in 39 patients. A significant reduction in circulating levels of PSA with Cernitin therapy indicated a reduction of cell lesions in BPH. In contrast, no such change occurred with beta-sitosterol treatment. Although flower pollen extract proved superior to beta-sitosterol in many respects, the mean values for residual volume fell under 15 ml for both at the end of treatment. Jodai et al [56] reported the results of a study on 32 patients with

chronic prostatitis given 6 tablets of Cernitin daily for an average of 12 weeks. Subjective symptoms improved in 74.2% of the subjects as compared to 65.6% for objective symptoms. The overall efficacy rate was 75.0%.

In a double-blind, placebo-controlled study, Becker et al [57] reported data for 96 subjects with BPH in stages II or III according to the Vahlensieck. Subjects received two Cernitin capsules or placebo three times daily for 12 weeks. The results showed significant improvement in nocturia (68.8% on Cernitin versus 37.2% on placebo,  $p = 0.005$ ), daytime frequency (65.8% on Cernitin versus 43.9% on placebo,  $p = 0.076$ ), freedom from daytime frequency (48.8% on Cernitin versus 19.5% on placebo,  $p = 0.010$ ) and freedom from sensation of residual urine (37.1% on Cernitin versus 7.7% on placebo,  $p = 0.016$ ). In addition there was significant improvement in global assessment scores of both the physicians ( $p = 0.001$ ) and patients ( $p = 0.01$ ). Physicians rated the overall response as very good or good for 68.1% of patients taking Cernitin versus 13.7% taking placebo group. 72.1% of patients taking Cernitin rated their overall response as very good or good versus 27.3% in the placebo group. However, there was no significant change in the size of the prostate as determined by palpation.

In an open study, Buck et al [58] studied the effect Cernitin, 2 tablets twice daily for up to 18 months on 15 patients with chronic, relapsing non-bacterial prostatitis and prostatic dysuria. Seven patients became symptom-free, 6 patients were significantly improved, and 2 patients failed to show improvement in symptoms. Improvement in symptomatology occurred for most patients after 3 months of treatment.

In a double-blind, placebo-controlled study, Buck et al [59] reported data for 53 subjects awaiting operative treatment for outflow obstruction due to prostate enlargement. Patients were instructed to take 2 capsules of Cernitin or placebo twice a day over a 6-month period. The results showed 60% of the subjects receiving Cernitin had less nocturia compared to 30% receiving placebo ( $p < 0.063$ ), and 57% showed improvement in bladder emptying with Cernitin compared to only 10% taking placebo ( $p < 0.004$ ). There was a significant difference ( $p < 0.009$ ) in overall improvement in subjective symptoms in the Cernitin group (69%) versus placebo (29%). Despite no significant change in peak urinary flow rate or voided volume, residual urinary volume decreased significantly in the Cernitin group compared to placebo ( $p < 0.025$ ).

In a double-blinded, active-control study, Maekawa et al [60] conducted a double-blind study comparing Cernitin, 2 capsules twice daily for 12 weeks, to Paraprost (a mixture of the amino acids L-glutamic acid, L-alanine, glycine) in 159 patients with BPH.

The two botanical preparations were comparable in improving symptoms (IPSS) from baseline (55% for Cernitin and 62% for Paraprost). There was a significant improvement in residual urinary volume, average flow rate, maximum flow rate and prostatic weight in the Cernitin group versus Paraprost. Greater than moderate effectiveness rating was 49.1% for Cernitin and 41.2% for Paraprost.

Becker et al [61] continued the placebo-controlled study described above [57] with an open label study in which 92 subjects previously treated in the first phase of the study with Cernitin ( $n=45$ ) or placebo ( $n=47$ ) were continued or now treated with Cernitin for 12 weeks. Physicians were blinded in this second phase as to whether the subjects received Cernitin or placebo in the first phase. The results showed that the differences observed between the two groups in the first phase were eliminated in the 2nd phase. Subjects previously treated with placebo improved significantly when treated with Cernitin. Significant improvements were observed in nocturia ( $p = 0.051$ ), frequency ( $p = 0.039$ ), feeling of incomplete emptying ( $p = 0.013$ ), palpable enlargement of the prostate ( $p = 0.046$ ) and prostatic congestion ( $p = 0.03$ ).

Bach and Ebeling [62] reported the results from a large open-label trial in Germany involving 208 physicians and 1798 patients with BPH capable of being evaluated. The patients were treated for 24 weeks with Cernitin; 2 tablets 3 times daily. The patients were divided into 3 groups (stage 1, 2 and 3) for data analysis based on the severity of the BPH symptoms. Patients in stage 1 had the most improvement of the three groups in irritative symptoms whereas patients in stage 2 had significant improvement in both irritative and obstructive symptoms. Peak urinary flow rates increased significantly in all 3 groups. A continuing improvement in symptoms was noted when comparing the results after 12 and 24 weeks of treatment. Efficacy in stage 1 and 2 patients was judged to be satisfactory or better in 90% of the patients. Efficacy in stage 3 patients was judged to be satisfactory or better in 65% of the patients. The authors concluded that treatment with Cernitin is justified even for stage 3 patients until surgery is performed.

Rugendorff et al [63] reported the results of a study on 90 patients with non-bacterial prostatic dysuria and chronic prostatitis. Subjects were given Cernitin, 1 tablet 3 times daily for 6 months. Seven-two patients were found to have complicating factors (such as bladder neck sclerosis, prostatic calculi or urethral stricture), while the remaining 18 possessed no complicating factors. Seventy-eight percent of the patients without complications responded to the treatment with 36% of these becoming asymptomatic. In contrast, only 6% of patients with complicating factors improved. Peak urine flow rate in the uncomplicated group increased

significantly ( $p < 0.001$ ) from 15.9 to 23.5 ml/s.

Braun and Peyer [64] in a 1993 double blind, placebo-controlled investigation on 44 patients with Grade I and II BPH assessed the validity of treatment with flower pollen extract on subjective and objective parameters. They found by using questionnaires, echography, and laboratory analysis of PSA that flower pollen extract had a clear benefit over placebo. In 25 patient receiving verum compared to 19 receiving placebo, there was a significant reduction in the mean number of both diurnal and nocturnal micturations with flower pollen extract ( $p < 0.05$ ). Using ultrasonic measures, the mean volume of the prostate decreased significantly more in the verum group (-29% vs. -8.8%,  $p < 0.05$ ). More reduction in residual urine volume and PSA levels were noted in the verum group.

Yasumoto and colleagues [65] conducted an open-label trial with 79 BPH patients. Patients were given 2 Cernitin tablets 3 times a day for at least 12 weeks. The results showed that symptom scores improved significantly from baseline. Overall clinical efficacy was rated 85%. Clinical efficacy at 12 weeks was rated satisfactory or better in 85% of the patients. Dutkiewicz [66] gave Cernitin to 51 patients with BPH -- 2 capsules three times daily for 2 weeks then 1 capsule 3 times daily for an additional 14 weeks. Thirty-eight subjects were given Tadenan (Pygeum africanum extract) for 4 months. Significant improvement in subjective symptoms was reported for both -- Cernitin group (78%) and the Tadenan group (55%). In a recently published study, 24 patients with chronic prostatitis (NIH-category III) were treated with Cernitin for at least 6 weeks. The results showed a significant decrease in the symptom scores at 4 and 6 weeks [67].

#### *Potential Role of Combination Therapy*

Although published clinical trials support the efficacy of Cernitin in the relief of mild to moderate LUTS, a precedent exists to examine beneficial effects of combining Cernitin with other botanical products. A recently completed clinical study sponsored by the National Institutes of Health concluded that the combination of finasteride and doxazosin was more effective than either treatment alone in preventing progression of BPH [68]. This study demonstrates the therapeutic advantages of combining drugs with different mechanisms of action.

The precise mechanisms behind the therapeutic benefits of Cernitin are not fully understood, but it is generally accepted that anti-inflammatory and/or alpha adrenergic blocking effects are important. Therefore, combining Cernitin with a botanical and/or prescription drug with different mechanisms of action may provide additional symptomatic relief. Two recently published trials using combinations of agents with Cernitin support this theory.

Preuss et al [69] reported on a double-blind, placebo-controlled trial comparing a combination of Cernitin (378 mg); saw palmetto fruit standardized to 43% B-sitosterol (286mg) and vitamin E (100IU). Seventy subjects completed the combination therapy and 57 subjects completed the placebo over a 90-day period. There was a significant reduction in nocturia ( $p < 0.001$ ), daytime frequency ( $p < 0.04$ ) and overall symptomatology as measured by the American Urological Association Symptom Score. This combination therapy is logical, since saw palmetto may have different mechanisms of action than Cernitin. As an example, it is believed that saw palmetto compared to Cernitin prevents to a greater extent the conversion of testosterone to dihydroxytestosterone, a potent androgen that stimulates enlargement of the prostate [17,21,22].

Aoki et al [70] conducted an open label trial to study tamsulosin hydrochloride (Flomax®), an alpha1A adrenoceptor antagonist, Cernitin, and the combination in 243 patients with symptomatic BPH over a 12-week period. The results showed that whereas symptoms improved in each group, supporting the efficacy of Cernitin, the best results were obtained in the group that used the combination.

#### **Discussion**

A review of placebo-controlled trials, active-controlled and open-label studies indicate that Cernitin is a safe and effective therapy for the management of mild to moderate LUTS. By reducing bothersome symptoms, Cernitin improves quality of life. The placebo-controlled, double-blind studies with Cernitin alone [47,57,59,60] and combined with other natural products [69] especially provide evidence that Cernitin is effective in reducing nocturia, daytime frequency, and sensation of residual urine. The number of subjects in these studies was small relative to the studies conducted for prescription therapeutics such as Terazosin [11] (Hytrin, minimum of 430 subjects) and Doxazosin [71] (Cardura, minimum of 900 subjects), however the duration of the studies were comparable. Cernitin studies were generally conducted for 12 to 24 weeks, terazosin trials were conducted for 12 to 24 weeks, and doxazosin studies were also conducted over a 14 to 16 week period.

Since the number of subjects studied in placebo-controlled trials is small, it was necessary to review open-label and active control studies as supporting data. Concerning the use of Cernitin alone, we report on 15 open label studies and 4 double-blind, placebo-controlled studies that showed consistent reduction in subjective symptoms and overall effectiveness ratings of 75% and greater. In addition, 1 double-blind, active-controlled study, 1 open-label study on a combination, and 1 double-blind, placebo-controlled

study on a combination strengthen the conclusions on the therapeutic merits of Cernitin.

## Conclusions

Sufficient evidence exists in the primary and secondary literature to indicate that a standardized flower pollen extract commonly referred to as Cernitin is safe and effective for the treatment of mild to moderate LUTS. This dietary supplement composed of pollen extracts from rye, corn, and timothy has the potential to be used in combination with other dietary supplements or pharmaceuticals to provide relief of bothersome symptoms and improve quality of life for millions of men.

## References

1. Jacobsen SJ, Girman CJ, Guess HA, Oesterling JE, Lieber MM: New diagnostic and treatment guidelines for benign prostatic hyperplasia. Potential impact in the United States. *Arch Int Med* 155:477-481, 1995.
2. Preuss HG, Adderly B: Benign prostatic hyperplasia: men's secret disease. In: *The Prostate Cure*. (eds) HG Preuss, B Adderly. Crown Publishing, Inc., New York, NY, pp 1-29, 1998.
3. Oesterling JE: Benign prostatic hyperplasia: a review of its histogenesis and natural history. *The Prostate Supplement*, 6:67-73, 1996.
4. Buttyan R, Chen M-W, Levin RM: Animal model of bladder outlet obstruction and molecular insights into the basis for the development of bladder dysfunction. *European Urology* 32(Suppl 1):32-39, 1997.
5. Knott MA, Bootman JL: The economics of benign prostatic hyperplasia treatment: a literature review. *Clinical Therapeutics* 18:1227-1241, 1995.
6. Salcedo H: *The Prostate. Facts and Misconceptions*. Birch Lane Press Book, New York, NY, 1993.
7. Berry SJ, Coffey DS, Walsh PC, Ewing LL: The development of human benign prostatic hyperplasia with age. *J Urol* 132:474-479, 1994.
8. Lytton B, Emery JM, Howard BM: The incidence of benign prostatic hyperplasia. *J Urol* 99:639-645, 1968.
9. Walsh PC, Worthington JF: *The Prostate. A Guide for Men and the Women Who Love Them*. Baltimore and London: The Johns Hopkins University Press, p 15, 1995.
10. Bruskewitz, R: Management of symptomatic BPH in the US: who is treated and how?, *Eur Urol* 36(Suppl 3):7-13, 1999.
11. Hytrin® (terazosin hydrochloride) Capsules, 01G-501-0118-1 Master, February 2001, <http://www.rxabbott.com/hy/hypi.htm>; accessed on 11/22/02.
12. Fowler FJ, Wenneberg JE, Timothy RP, et al: Symptom status and quality of life following prostatectomy. *JAMA* 259:3018-3022, 1988.
13. Breu W, Stadler F, Hagenlocher M, Wagner H: Der sabalfrucht-extrakt SG 291. Ein phytotherapeutikum zur behandlung der benignen prostatahyperplasie. *Zeitschrift Fur Phytotherapie* 13:107-115, 1992.
14. Breu W, Hagenlocher M, Redl K, et al: Antiphlogistische wirkung eines mit hyperkritischem kohlendioxid gewonnenen sabalfrucht-extraktes. *Arzneim Forsch Drug Research* 42:547-551, 1992.
15. Stenger A, Tarayre JP, Carilla F: Etude pharmacologique et biochimique de l'extrait hexanique de serenoa repens. *B: Gaz Med de France* 89:2041-2048, 1982.
16. Rhodes L, Primka RL, Berman C et al: Comparison of finasteride (Proscar), a 5<sub>α</sub> reductase inhibitor, and various commercial plant extracts in in vitro and in vivo 5<sub>α</sub> reductase inhibition. *The Prostate* 22:43-51, 1993.
17. Sultan C, Terraza A, Divillier C: Inhibition of androgen metabolism and binding by a liposterolic extract of Serenoa repens B in human foreskin fibroblasts. *J Steroid Biochem* 20:515-521, 1984.
18. Carilla E, Briley M, Fauran F, Sultan C, Duvilliers C: Binding of Permixon, a new treatment for prostatic benign hyperplasia, to the cytosolic androgen receptor in the rat prostate. *J Steroid Biochem* 20:521-523, 1984.
19. Champault G, Patel JC, Bonnard AM: A double-blind trial of an extract of the plant Serenoa repens in benign prostatic hyperplasia. *Br J Clin Pharmacol* 18:461-462, 1984.
20. Carraro JC, Raynaud JP, Koch G, et al: Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1,098 patients. *The Prostate*. 29:231-240, 1996.
21. Posker GL, Brogden RN: Serenoa repens (Permixon). A review of its pharmacology and therapeutic efficacy in benign prostatic hyperplasia. *Drug and Aging* 9:379-395, 1996.
22. Denis LJ: Editorial review of Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1,098 patients. *The Prostate* 29:241-242, 1996.
23. Braeckman J: The extract of Serenoa repens in the treatment of benign prostatic hyperplasia: a multicenter open study. *Curr Therap Res* 56:776-785, 1994.
24. Champault G, Bonnard AM, Cauquil J, Patel JC: Medical treatment of prostatic adenoma. Controlled trial PA 109 vs placebo in 110 patients. *Ann Urol* 18:407-410, 1984.
25. Steinman D: Enlarged prostate? Try tree bark. *Natural Health* 24:46-47, 1994.
26. Barlet A, Albrecht J, Aubert A, Fisher M, Grof F, Grothuesmann HG, Masson JC, Mazeman E, Mermon R, Reichert H: Efficacy of Pygeum Africanum extract in the medical therapy of urination disorders due to benign prostatic hyperplasia: evaluation of objective and subjective parameters. A placebo-controlled double-blind multicenter study. *Wiener Klinische Wochenschrift*. 102:667-673, 1990.
27. Lichius JJ, Muth C: The inhibiting effects of Urtica dioica root extracts on experimentally induced prostatic hyperplasia in the mouse. *Planta Medica* 63:307-310, 1997.
28. Hirano T, Homma M, Oka K: Effects of stinging nettle roots and their steroidal components on the

- Na<sup>+</sup>, K<sup>+</sup> ATPase of the benign prostatic hyperplasia. *Planta Medica* 60:30-33, 1994.
29. Berges RR, Windeler J, Trampisch HJ, et al: Randomized, placebo-controlled clinical trial of  $\beta$ -sitosterol in patients with benign prostatic hyperplasia. *The Lancet* 345:1529-1532, 1995.
  30. Klippel KF, Hiltl DM, Schipp B: A multicenter, placebo-controlled, double-blind clinical trial of  $\beta$ -sitosterol (Phytosterol) for the treatment of benign prostatic hyperplasia. *Br J Urol* 80:427-432, 1997.
  31. Asplund A: Searching for the source of life and vitality. Sanomin (SA) SDN, Singapore, p 36, 1991.
  32. Meares Jr EM: Prostatitis and related disorders. In: Campbell's Urology, 6th edition. (ed) PC Walsh, Philadelphia, PA, pp 807-822, 1992.
  33. Loschen, G, Ebeling L: Hemmung der Arachidons-ureKaskade durch emen Extrakt aus Roggenpollen. *Arzneim-Forsch./Drug Res* 41:162-167, 1991.
  34. Ito R, Ishi M, Yamashita S, et al: Cernitin $\square$ pollen-extract (Cernilton $\text{\textcircled{R}}$ ): Anti-prostatic hypertrophic action of Cernitin $\square$  pollen extract *Pharmacometrics* 31:214, 1986.
  35. Hanamoto M, Liao M, Suzuki H, et al: Effect of Cernitin pollen-extract on the sex-hormone-induced nonbacterial prostatitis in rats. *Jpn Pharmacol Ther* 11:65, 1998.
  36. Wagner B, Otto H, Becker S, Schroder S, Klosterhalfen H: Experimental treatment studies with Cernilton N in human benign prostatic hyperplasia. In: *Benign Prostatic Diseases*. (eds) W Vahlensieck, G Rutishauser, Georg Thieme Verlag, Stuttgart, Germany and Thieme Medical Publishers, Inc. New York, NY, pp 123-127, 1992.
  37. Kamijo T, Sato S, Kitamura T: Effect of Cernitin Pollen-Extract on Experimental Nonbacterial Prostatitis in Rats. *Prostate* 49:122-131, 2001.
  38. Bales GT, Christiano AP, Kirsh EJ, Gerber GS: Phytotherapeutic agents in the treatment of lower urinary tract symptoms: a demographic analysis of awareness and use at the University of Illinois. *Urology* 54: 86-89, 1999.
  39. Schulz, V, Hansel R, Tyler VE: Rational Phytotherapy, A Physicians' Guide to Herbal Medicine, 3rd Edition, Springer, Berlin, 230-231, 1998.
  40. Rye Grass Monograph, Natural Medicines Comprehensive Database, Therapeutic Research Faculty, Stockton, Ca, p 919, 2000.
  41. MacDonald R, Ishani A, Rutks I, Wilt TJ: A systematic review of Cernilton for the treatment of benign prostatic hyperplasia. *BJU Int* 85:836-841, 1999.
  42. Wilt T, MacDonald R, Ishani A, Rutks I, Stark G: Cernilton for benign prostatic hyperplasia. *Cochrane Database Syst Rev* (2), CD001042, 2000.
  43. Shoskes DA: Phytotherapy and other alternative forms of care for the patient with prostatitis. *Curr Urol Rep* 3:330-334, 2002.
  44. Vahlensieck W, Rutishauser G (eds): *Benign Prostatic Diseases*. Georg Thieme Verlag, Stuttgart, Germany and Thieme Medical Publishers, Inc. New York, NY, pp 1-207, 1992.
  45. Clouatre D: *Pollen Extract for Prostate Health*. Pax Publishing, San Francisco, CA, pp 1-30, 1997.
  46. Stoffe JA, Clouatre D: *The Prostate Miracle*. Kensington Books, New York, NY, pp 1-261, 2000.
  47. Leander G: A preliminary investigation on the therapeutic effect of Cernilton N in chronic prostatovesiculitis. *Svenska Lakartidningen* 59:3296, 1962.
  48. Inada T, Kitagawa T, Miyakawa M: Use of Cernilton in patients with prostatic hypertrophy. Tobishi Pharmaceutical Co, Ltd. Tokyo, Japan, 1966.
  49. Ohkoshi M, Kawamura N, Nagakubo I: Clinical evaluation of Cernitin in chronic prostatitis. *Japanese Journal of Urology*, 21:73-85, 1967.
  50. Takeuchi H, Yamauchi A, Ueda T et al: Quantitative evaluation on the effectiveness of Cernilton on benign prostatic hypertrophy. *Hinyoki Kiyo* 27:326-327, 1981.
  51. Horii A, Iwai S, Maekawa M, Tsujita, M: Clinical evaluation of Cernilton in the treatment of the benign prostatic hypertrophy. *Hinyo Kiyo* 31:739-746, 1985.
  52. Ueda K, Kinno H, Tsujimura S: Clinical evaluation of Cernilton on benign prostatic hyperplasia. *Hinyo Kiyo*, 31:187-191, 1985.
  53. Hayashi J, Mitsui, H, Yamakawa G, et al: Clinical evaluation of Cernilton in benign prostatic hypertrophy. *Hinyo Kiyo*, 32:135-141, 1986.
  54. Ebeling L: The therapeutic results of defined pollen extract in patients with chronic prostatitis. In: Schmiedt E, Alken JE, Bauer HW (eds). *Therapy of Prostatitis*. Zuckschwerdt Verlag, Munchen, pp 154-160, 1986.
  55. Brauer H: The treatment of benign prostatic hyperplasia with phytopharmacia: a comparative study of Cernilton and beta sitosterol. *Therapeiwoche* 36: 1686-1696, 1986.
  56. Jodai A, Maruta N, Shimomae E, et al: A long-term therapeutic experience with Cernilton in chronic prostatitis. *Hinyo Kiyo* 34:561-568, 1988.
  57. Becker H, Ebeling, L: Conservative treatment of benign prostatic hyperplasia (BPH) with Cernilton. Results of a placebo-controlled double-blind study. *Urologe(b)* 28:301-306, 1988.
  58. Buck AC, Rees RWM, Ebeling L: Treatment of chronic prostatitis and prostatodynia with pollen extract. *Br J Urol* 64:496-499, 1989.
  59. Buck AC, Cox R, Rees, W, Ebeling L, and John A: Treatment of outflow tract obstruction due to benign prostatic hyperplasia with the pollen extract, Cernilton. A double-blind, placebo-controlled study. *Br. J. Urol.* 66:398-404, 1990.
  60. Maekawa M, Kishimoto T, Yasumoto R, et al: Clinical evaluation of Cernilton on benign prostatic hypertrophy - a multiple center double-blind study with Paraprost. *Hinyo Kiyo*, 36:495-516, 1990.
  61. Becker H, Ebeling L: Phytotherapy of BPH with Cernilton. Results of a controlled prospective study. *Urologe (B)* 31:113-116, 1991.
  62. Bach D, Ebeling L: Possibilities and limitations of phytotherapy for benign prostatic hyperplasia (BPH): results of treatment with Cernilton N for stages I-III according to Alken (or II-IV according to Vahlensieck). In: *Benign Prostatic Diseases*. W Vahlensieck, G Rutishauser (eds). Georg Thieme Verlag, Stuttgart, Germany pp 180-187, 1992.
  63. Rugendorff EW, Weidner W, Ebeling L, Buck AC: Results of treatment with pollen extract (Cernilton $\_$ ) in prostatodynia and chronic prostatitis. *Br J Urol* 71:433-438, 1993.
  64. Braun L, Peyer P, Ackermann, et al: A multicentre, placebo-controlled study on the efficacy and tolerability of adenoprostal in patients with benign

- prostatic hyperplasia (BPH). Tribuna Medica Ticinese, 1993.
65. Yasumoto R, Kawanishi H, Tsujino T, et al: Clinical evaluation of long-term treatment using Cernilton pollen extract in patients with benign prostatic hyperplasia. Clin Ther 17:82-87, 1995.
  66. Dutkiewicz S: Usefulness of Cernilton in the treatment of benign prostatic hyperplasia. Int Urol Nephrol 28:49-53, 1996.
  67. Monden K, Tsugawa M, Ninomiya Y, Ando E, Kumon H: A Japanese version of the National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI: Okayama version) and the clinical evaluation of cernitin pollen extract for chronic non-bacterial prostatitis. Nippon Hinyo Gakkai Zasshi 93:539-547, 2002.
  68. National Institutes of Health, "Two-Drug Therapy is Best for Symptomatic Prostate Enlargement, Combination Should Change Clinical Practice", NIH News Release, May 28, 2002 ([www.nih.gov/news/pr/may2002/niddk-28.htm](http://www.nih.gov/news/pr/may2002/niddk-28.htm)).
  69. Preuss HG, Marcusen C, Regan J, et al: Randomized trial of a combination of natural products (cernitin, saw palmetto, B-sitosteriol, vitamin E) on symptoms of benign prostatic hyperplasia (BPH). Int Urol and Neph 33:217-225, 2001.
  70. Aoki A, Naito K, Hashimoto O, et al: Clinical evaluation of the effect of tamsulosin hydrochloride and cernitin pollen extract on urinary disturbance associated with benign prostatic hyperplasia in a multicentered study. Hinyo Kyo, 48:259-267, 2002.
  71. Cardura® (doxazosin mesylate) Tablets, 70-4538-00-8 [www.pfizer.com/hml/pi's/cardurapi.pdf](http://www.pfizer.com/hml/pi's/cardurapi.pdf); accessed on 11/24/02.

Effects of Pollen-Extract Components, Diamines and Derivatives of Feruloylputrescine on Isolated Bladder and Urethral Smooth Muscles of Mice.

**Nakase K, Kimura I, Kimura M.**

Department of Chemical Pharmacology, Faculty of Pharmaceutical Sciences, Toyama Medical and Pharmaceutical University, Japan.

Jpn J Pharmacol. 1990 Jun; 53(2):157-64.

The contracting or inhibitory effects of pollen-extract components, diamines and derivatives of feruloylputrescine (FP) were investigated on the isolated bladder or urethral smooth muscles of mice. Among the nine diamines ( $\text{NH}_2(\text{CH}_2)_n\text{NH}_2$ ,  $n = 2-10$ ) tested, five of them with shorter carbon chains ( $n = 2-6$ ) (0.1-30.0 mM) only slightly contracted the bladder strips and to some extent inhibited the noradrenaline (NA, 1.77  $\mu\text{M}$ )-induced contraction of urethral strips. 1,5-Diaminopentane (C5), a component of the pollen-extract, inhibited most effectively the NA-induced contraction of urethral strips with an  $\text{IC}_{50}$  value of 2.3 mM (95% confidence limit: 2.0-2.6 mM). FP, also a component of the pollen-extract, inhibited the NA-induced contraction of urethral strips in a non-competitive manner, producing 32.5  $\pm$  5.5% ( $N = 5$ ) inhibition at 378  $\mu\text{M}$ . Among the derivatives of FP, feruloylcadaverine inhibited urethral contraction most potently, producing 46.3  $\pm$  7.1% ( $N = 5$ ) inhibition at 359  $\mu\text{M}$ . These derivatives had no effect on bladder contraction. In contrast, four diamines with longer carbon chains ( $n = 7-10$ ) contracted the bladder strips (3-30 mM) and potentiated the NA-induced contraction of urethral strips (10  $\mu\text{M}$ -3 mM). Thus, the components of the pollen-extract, FP and C5, potently inhibited urethral contraction, which may facilitate the discharge of urine in vivo.

PMID: 2385002 [PubMed - indexed for MEDLINE]

## Effect of Cernitin pollen-extract (Cernilton®) on the Function of Urinary Bladder in Conscious Rats

Akiko Nagashima, Makoto Ishii, Masaichi Yoshinaga and Etsuji Higaki

*Ome Research Laboratories, Tobishi Pharmaceutical Co., Ltd.,  
7-1, 1-chome, Suehiro-cho, Ome-shi, Tokyo 198-0025, Japan*

We studied the effect of Cernitin pollen-extract (Cernilton®, CN-009), a preparation made from eight kinds of pollen such as timothy, rye, and maize etc., on the function of urinary bladder in conscious rats using the method that reported previously by Kontani *et al.*

The surgical procedure was performed under ether anesthesia, and after the recovery, the rat was restricted in a Ballman cage during the experiment. The bladder contraction was induced by the constant infusion of physiological saline. The effect of CN-009 was evaluated by using the following parameters measured from the cystometrogram; number of micturition (NM, times/hr), micturition threshold pressure (MTP, cmH<sub>2</sub>O) and peak pressure during bladder contraction (PP, cmH<sub>2</sub>O).

The single administration of CN-009 (630 and 1260 mg/kg, i.d.) did not affect the three parameters mentioned above. On the other hand, administered CN-009 (630 or 1260 mg/kg, p.o. for 6 or 13 days and i.d. on the very day of the experiment) for 7 or 14 successive days increased PP in the dose- and time- dependent manners, and the PP was increased significantly ( $p < 0.05-0.01$ ) on the group administered high dose for long period compared to that of control group. CN-009 did not affect NM and MTP much.

These results suggested that CN-009 administered sub acutely enhanced PP and promoted the function of urinary bladder.

### KEY WORDS

Cernitin pollen-extract, Cernilton, CN-009, Urinary bladder function, Cystometrogram, Conscious rats

## A Critical Review of Graminex Flower pollen extract for Symptomatic Relief Of Lower Urinary Tract Symptoms (LUTS) in Men

Walter G. Chambliss, Ph.D.

National Center for Natural Products Research, Research Institute of Pharmaceutical Sciences, University of Mississippi, University, Ms. 38677

January 12, 2003

### Objective

To review published data concerning the ability of a Graminex's Flower Pollen Extract to provide symptomatic relief in men suffering from lower urinary tract symptoms (LUTS).

### Introduction

The National Institutes of Health (NIH) estimates 9 million men suffer from symptoms related to an enlarged prostate and 400,000 surgeries are conducted each year in the U.S.<sup>1</sup> The term lower urinary tract symptoms (LUTS) is used to describe symptomatology in men who are experiencing one or more symptoms on the International Prostate Symptom Score (IPSS) questionnaire that includes urgency, daytime and nighttime urinary frequency, hesitancy, intermittency, sensation of incomplete voiding, and force of urine stream.<sup>2</sup> LUTS is used to describe urinary tract disorders in men with benign prostate hyperplasia (BPH), prostatodynia, acute and chronic prostatitis caused by a bacterial infection and acute and chronic abacterial prostatitis.

Bruskewitz stated the primary aim of pharmacological treatment is to improve quality of life by relieving bothersome symptoms since serious complications from BPH are rare<sup>3</sup>. However, he reported the results of a study conducted in the U.S. that showed Urologists gave no treatment 77% of the time to men with mild symptoms. Prescription drugs were given 89% of the time and surgery was conducted on 1% of the time for men with moderate symptoms. The primary therapeutic treatment was alpha(1)-adrenoceptor antagonists such as terazosin hydrochloride (Hytrin®) that provides symptomatic relief but has not been shown to provide long-term effects on the incidence of surgery, acute urinary obstruction or other complications of BPH.<sup>4</sup> The need exists for safe, effective products that can be used by men to treat mild to moderate LUTS in lieu of or in addition to prescription drugs. This review focuses on

the potential for flower pollen extract, a dietary supplement, to fill this therapeutic void.

Graminex Flower Pollen Extract is a standardized extract of rye pollen (*Secale cereale*), corn pollen (*Zea mays*) and timothy pollen (*Phleum pratense*). The extract contains a blend of water-soluble and lipid-soluble fractions and is available around the world under other brand names such as Cernitin, and in capsule and tablet forms as Cernilton. In vitro<sup>5</sup> and animal model studies<sup>6</sup> have shown that both fractions have anti-inflammatory properties through inhibition of the prostaglandin and leukotrien synthesis. The water-soluble fraction has been shown to reduce the size of the ventral and dorsal prostate in the rat<sup>7</sup> and to inhibit testosterone-induced BPH in castrated animals<sup>8</sup>. Both fractions have been shown to relax the smooth muscle of the mouse and pig urethra, increase bladder muscle contractions<sup>8</sup> and reduce prostate size in mature Wistar rats<sup>9</sup>.

### Methods

Literature searches were conducted on Medline and the Cochrane Library. Secondary sources such as review articles and monographs in botanical reference books were included in the analysis. Open label and comparative trials were included in the assessment, although more weight was placed on placebo-controlled, double-blind studies. Emphasis was placed on subject ratings of symptoms in light of the potential for self-medication of this extract.

### Results

## Secondary Literature

Four reviews of the clinical efficacy and safety of flower pollen extract have been published in the past 8 years. Although each used their own criteria in selecting valid studies they all concluded that flower pollen extract was very safe with few or no side effects so summaries below are limited to efficacy.

Commission E, an expert committee established by the German government to evaluate the safety and efficacy of over 300 botanical and botanical combinations sold in Germany, concluded in 1994 that the combination extract of rye, corn and timothy pollen was useful in the treatment of "micturition difficulties associated with Alken stage I-II benign prostatic enlargement (BPH)".<sup>10</sup>

The Natural Medicines Comprehensive Database concluded that rye grass pollen extract (Cernilton®) was "possibly effective" for the management of BPH symptoms, for shrinking prostate size and when used for prostatitis and prostatodynia.<sup>11</sup>

McDonald et al concluded in reviews published in 1999<sup>12</sup> and 2000<sup>13</sup> that results from 4 double-blind studies (444 men in total, 2 studies with placebo; 2 with active controls) consistently showed a "modest" improvement in subjective symptoms and nocturia in the flower pollen extract groups compared to placebo, and 2 control products, Paraprost and Tadernan, although the authors called for additional studies to evaluate long-term effects.

Shoskes concluded that there was credible clinical and scientific evidence that treatment with flower pollen extract was efficacious for the majority of patients with nonbacterial prostatitis and prostatodynia.<sup>14</sup>

## Primary Literature

Flower pollen extract was well tolerated in all of the published studies with minimal reported side effects therefore the discussion will be limited to efficacy considerations.

### *Double-Blind, Placebo-Control Studies*

Two double-blind, placebo-controlled studies have been published with a total of 149 subjects. Becker et al<sup>15</sup> reported data for 96 subjects with BPH in stages II or III according to the Vahlensieck. Subjects received 2 Cernilton® capsules or placebo three times daily for 12 weeks. The results showed significant improvement in nocturia (68.8% on Cernilton® versus 37.2% on placebo), daytime frequency (65.8% on Cernilton® versus 43.9% on placebo), freedom from daytime frequency (48.8% on Cernilton® versus 19.5% on placebo) and freedom from sensation of residual urine (37.1% on Cernilton®

versus 7.7% on placebo). In addition there was significant improvement in global assessment scores of both the physicians and patients. Physicians rated the overall response as very good or good for 68.1% on Cernilton® versus 13.7% on placebo. Patients rated the overall response as very good or good for 72.1% on Cernilton® versus 27.3% on placebo. There was no significant change in the size of the prostate as determined by palpitation.

Buck et al<sup>16</sup> reported data for 53 subjects awaiting operative treatment for outflow obstruction due to prostate enlargement. Patients were instructed to take 2 capsules of Cernilton® or placebo twice a day over a 6-month period. The results showed 60% of the subjects on Cernilton® had improve nocturia compared to 30% on placebo ( $p < 0.063$ ), 57% showed improvement in bladder emptying compared to only 10% on placebo. There was a significant difference in overall improvement in subjective symptoms in the Cernilton® group (69%) versus placebo (29%). There was no significant change in peak urine flow rate or voided volume. Residual urine volume decreased significantly in the Cernilton® group compared to placebo.

### *Double-Blind, Active-Control Studies*

Maekawa M., et al<sup>17</sup> conducted a double-blind study comparing Cernilton®, 2 capsules twice daily for 12 weeks to Paraprost (a mixture of the amino acids L-glutamic acid, L-alanine, glycine) in 159 patients with BPH. The two supplements were comparable in improving symptoms from baseline (55% for Cernilton® and 62% for Paraprost). There was a significant improvement in residual urinary volume, average flow rate, maximum flow rate and prostatic weight in the Cernilton® group versus Paraprost. Greater than moderate effectiveness rating was 49.1% for Cernilton® and 41.2% for Paraprost.

### *Open Label Studies*

Eleven published open label studies with a total of 2291 subjects were reviewed. The results indicate significant beneficial effects in subjective LUTS when Cernilton® is used on average for 13.6 weeks.

Becker et al<sup>18</sup> continued the placebo-controlled study<sup>15</sup> described above with an open label study in which 92 subjects previously treated in the first phase of the study with Cernilton® (n=45) or placebo (n=47) were treated with Cernilton® for 12 weeks. Physicians were blinded as to whether the subjects received Cernilton® or placebo in the first phase. The results showed that the differences observed between the two groups in the first phase were eliminated in the 2<sup>nd</sup> phase. Subjects previously treated with placebo improved significantly when treated with Cernilton®. Significant improvements were observed in nocturia, frequency, feeling of incomplete emptying,

palpable enlargement of the prostate and prostatic congestion.

Hayashi et al<sup>19</sup> treated 20 BPH patients with Cernilton®, 6 tablets a day for an average of 13.2 weeks. They reported improvements in sense of residual urine (92%), retardation (86%), night frequency (85%), strain on urination (56%), protraction (53%), and forceless urinary stream (53%). Overall subjective effectiveness was 80% and overall objective effectiveness was 54%. Overall effectiveness was rated 80%.

Yasumoto and colleagues<sup>20</sup> conducted an open label trial with 79 BPH patients. Patients were given 2 Cernilton® tablets 3 times a day for at least 12 weeks. The results showed that symptom scores improved significantly from baseline. Overall clinical efficacy was rated 85%. Clinical efficacy at 12 weeks was rated satisfactory or better in 85% of the patients.

Bach and Ebeling<sup>21</sup> reported the results from a large open label trial in Germany involving 208 physicians and 1798 evaluable patients with BPH. The patients were treated for 24 weeks with Cernilton®; 2 tablets 3 times daily. The patients were divided into 3 groups (stage 1, 2 and 3) for data analysis based on the severity of the BPH symptoms. Patients in stage 1 had the most improvement of the three groups in irritative symptoms whereas patients in stage 2 had significant improvement in both irritative and obstructive symptoms. Peak urine flow rate increased significantly in all 3 groups. A continuing improvement in symptoms was noted when comparing the results after 12 and 24 weeks of treatment. Efficacy in stage 1 and 2 patients was judged to be satisfactory or better in 90% of the patients. Efficacy in stage 3 patients was judged to be satisfactory or better in 65% of the patients. The authors concluded that treatment with Cernilton® is justified even for stage 3 patients until surgery is performed.

Dutkiewicz<sup>22</sup> reported on a study in 51 patients with BPH were given Cernilton®, 2 capsules three times daily for 2 weeks then 1 capsule 3 times daily for an additional 14 weeks. Thirty-eight subjects were given Tadenan (Pygeum africanum extract) for 4 months. Significant improvement in subjective symptoms was reported for the Cernilton® group (78%) versus the Tadenan group (55%).

Horii et al<sup>23</sup> reported the results of 30 subjects with BPH who were given Cernilton®; 2 tablets, 3 times daily for at least 12 weeks. The overall clinical efficacy for subjective symptoms was rated at 80% and objective symptoms at 43%.

Ueda et al<sup>24</sup> treated 22 patients with stage I and II BPH with Cernilton® for over 4 weeks. Eighty-two percent of the patients were rated as moderately improved or better.

In a recently published study 24 patients with chronic prostatitis (NIH-category III) were treated with Cernilton® for at least 6 weeks. The results showed a significant decrease in the symptom scores at 4 and 6 weeks.<sup>25</sup>

In another open study, Buck et al<sup>26</sup> studied the effect Cernilton®, 2 tablets twice daily for up to 18 months on 15 patients with chronic, relapsing abacterial prostatitis and prostodynia. Seven patients became symptom-free, 6 patients were significantly improved and 2 patients failed to show improvement in symptoms. Improvement in symptomatology occurred for most patients after 3 months of treatment.

Jodai et al<sup>27</sup> reported the results of a study on 32 patients with chronic prostatitis given 6 tablets of Cernilton® daily for an average of 12 weeks. Subjective symptoms improved in 74.2% of the subjects and objective symptoms improved in 65.6%. The overall efficacy rate was 75%.

Rugendorff et al<sup>28</sup> reported the results of a study on 90 patients with abacterial prostatic pain and chronic prostatitis. Subjects were given Cernilton®, 1 tablet 3 times daily for 6 months. Seven-two patients were identified as without complicating factors (such as bladder neck sclerosis, prostatic calculi or urethral stricture) and the remaining 18 with complicating factors. Seventy-eight percent of the patients without complications responded to the treatment with 36% of these becoming asymptomatic whereas only 6% of patients with complicating factors improved. Peak urine flow rate in the uncomplicated group increased significantly from 15.9 to 23.5 ml/s.

## Discussion

A review of 2 placebo controlled trials and 11 open label studies indicate that flower pollen extract is a safe and effective therapy for the management of mild to moderate LUTS. The studies showed a consistent reduction in subjective symptoms and overall effectiveness ratings of 75% and greater. The extract reduces bothersome symptoms thereby improving quality of life. The two placebo-controlled, double-blind studies provide evidence that the extract is effective in reducing nocturia, daytime frequency and sensation of residual urine.

### *Potential Role of Combination Therapy*

Although published clinical trials support the safety and efficacy of flower pollen extract in the relief of mild to moderate LUTS, a precedent exists to examine beneficial effects of combining flower pollen extract with other dietary supplement or pharmaceutical products. A recently completed clinical study sponsored by the National Institutes of Health concluded that the combination of 2 prescription drugs, finasteride and doxazosin were

more effective than either treatment alone in preventing progression of BPH.<sup>1</sup> This study demonstrates the therapeutic advantages of combining pharmacologically active constituents with different mechanisms of action.

Although the mechanism of action of flower pollen extract is not fully understood, it appears to work via an anti-inflammatory effect, therefore a combination with a botanical or prescription drug that works via a different mechanism may provide additional symptomatic relief. Two recently published trials on combinations with flower pollen extract are very encouraging. Preuss et al<sup>29</sup> reported on a double-blind, placebo controlled trial comparing a combination of flower pollen extract (378 mg), saw palmetto fruit standardized to 43% B-sitosterol (286mg) and vitamin E (100 IU). Seventy subjects completed the combination therapy and 57 subjects completed the placebo over a 90-day period. There was a significant reduction in nocturia, daytime frequency and overall symptomatology as measured by the American Urological Association Symptom Score. This combination therapy is logical since saw palmetto may have a different mechanism of action than flower pollen extract. It is generally believed that Saw Palmetto prevents the conversion of testosterone to dihydroxytestosterone, a potent androgen that stimulates enlargement of the prostate<sup>30</sup>.

Aoki et al<sup>31</sup> conducted an open label trial to study tamsulosin hydrochloride (Flomax®), an alpha1A adrenoceptor antagonist, flower pollen extract and their combination in 243 patients with symptomatic BPH over a 12 week period. The results showed that whereas symptoms improved in each group, supporting the efficacy of flower pollen extract, the best results were obtained in the group that used the combination product.

## Conclusions


Sufficient evidence exists in the primary and secondary literature to indicate that Graminex's Flower Pollen Extract is safe and effective for the treatment of mild to moderate LUTS. This dietary supplement ingredient has the potential to be used in combination with other dietary supplements or pharmaceuticals to provide relief of bothersome symptoms and improve quality of life for millions of men with this common condition.

## References

1. National Institutes of Health, "Two-Drug Therapy is Best for Symptomatic Prostate Enlargement, Combination Should Change Clinical Practice", NIH News Release, May 28, 2002 ([www.nih.gov/news/pr/may2002/niddk-28.htm](http://www.nih.gov/news/pr/may2002/niddk-28.htm)).
2. Denis L.J., Editorial review of "Comparison of phytotherapy (Permixon®) with finasteride in the treatment of benign prostates hyperplasia: A

- randomized international study of 1098 patients," *Prostate* 29:241-242, 1996.
3. Bruskewitz, R., "Management of symptomatic BPH in the US: who is treated and how?", *Eur Urol* 1999, 36, Suppl 3:7-13, 1999.
4. Hytrin® (terazosin hydrochloride) Capsules, 01G-501-0118-1 Master, February 2001, <http://www.rxabbott.com/hy/hypi.htm>; accessed on 11/22/02.
5. Loschen, G. and Ebeling, L., "Hemmung der Arachidons-ureKaskade durch emen Extrakt aus Roggenpollen. *Arzneim-Forsch./Drug Res*.41:162-167, 1991.
6. Ito, R., Ishi, M., Yamashita, S., et al., "Cernitin™ pollen-extract (Cernilton®): Anti-prostatic hypertrophic action of Cernitin™ pollen extract", *Pharmacometrics* 31:214, 1986.
7. Hanamoto, M., Liao, M., Suzuki, H., et al., "Effect of Cernitin pollen-extract on the Sex-hormone-induced Nonbacterial Prostatitis in Rats", *Jpn Pharmacol Ther.*, 11:65, 1998.
8. Kamijo, T., Sato, S. and Kitamura, T., "Effect of Cernitin Pollen-Extract on Experimental Nonbacterial Prostatitis in Rats", *Prostate* 49:122-131, 2001.
9. Bales G.T., Christiano A.P., Kirsh E.J., Gerber G.S., "Phytotherapeutic agents in the treatment of lower urinary tract symptoms: a demographic analysis of awareness and use at the University of Illinois", *Urology*, 54: 86-89, 1999.
10. Schulz, V., Hansel, R., Tyler, V.E., Rational Phytotherapy, A Physicians' Guide to Herbal Medicine, 3rd Edition, Springer, Berlin, 230-231, 1998.
11. Rye Grass Monograph, Natural Medicines Comprehensive Database, Therapeutic Research Faculty, Stockton, Ca., 919, 2000.
12. MacDonald, R., Ishani, A., Rutks, I., and Wilt, T.J., "A systematic review of Cernilton for the treatment of benign prostatic hyperplasia", *BJU Int.* 85:836-841, 1999.
13. Wilt, T., MacDonald, R., Ishani, A., Rutks, I., and Stark, G., "Cernilton for benign prostatic hyperplasia", *Cochrane Database Syst Rev.*, (2), CD001042, 2000.
14. Shoskes, D.A., "Phytotherapy and other alternative forms of care for the patient with prostatitis", *Curr Urol Rep* 3(4):330-334, 2002.
15. Becker, H., and Ebeling, L., "Conservative treatment of benign prostatic hyperplasia (BPH) with Cernilton®. Results of a placebo-controlled double-blind study", *Urologe(b)* 28:301-306, 1988.
16. Buck, A.C., Cox, R., Rees, W.M., Ebeling, L., and John, A., "Treatment of outflow tract obstruction due to benign prostatic hyperplasia with the pollen extract, Cernilton®. A double-blind, placebo-controlled study", *Br. J. Urol.* 66:398-404, 1990.
17. Maekawa, M., Kishimoto, T., Yasumoto, R., et al, "Clinical evaluation of Cernilton on benign prostatic hypertrophy – a multiple center double-blind study with Paraprost", *Hinyo Kyo*, 36:495-516, 1990.
18. Becker, H., and Ebeling, L., "Phytotherapy of BPH with Cernilton®. Results of a controlled prospective study", *Urologe (B)* 31:113-116, 1991.
19. Hayashi J., Mitsui, H., Yamakawa, G., et al., "Clinical evaluation of Cernilton® in benign prostatic hypertrophy", *Hinyo Kyo*, 32:135-141, 1986.

20. Yasumoto, R., Kawanishi H., Tsujino, T., et al, "Clinical evaluation of long-term treatment using Cernilton® pollen extract in patients with benign prostatic hyperplasia", *Clin Ther* 17:82-87, 1995.
21. Bach, D., and Ebeling, L., "Possibilities and Limitations of Phytotherapy for Benign Prostatic Hyperplasia (BPH): Results of Treatment with Cernilton®N for Stages 1-3 according to Alken (or II-IV according to Vahlensieck)", [www.graminex.com/clinical\\_studies/study12\\_sum.php](http://www.graminex.com/clinical_studies/study12_sum.php), unpublished report.
22. Dutkiewicz, S., "Usefulness of Cernilton in the treatment of benign prostatic hyperplasia", *Int Urol Nephrol* 28:49-53, 1996.
23. Horii, A., Iwai, S., Maekawa, M. and Tsujita, M., "Clinical evaluation of Cernilton in the treatment of the benign prostatic hypertrophy", *Hinyo Kiyo* 31:739-746, 1985.
24. Ueda, K., Kinno, H. and Tsujimura, S., "Clinical evaluation of Cernilton on benign prostatic hyperplasia", *Hinyo Kiyo*, 31:187-191, 1985.
25. Monden, K., Tsugawa, M., Ninomiya, Y., Ando, E., and Kumon, H., "A Japanese version of the National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI: Okayama version) and the clinical evaluation of cernitin pollen extract for chronic non-bacterial prostatitis", *Nippon Hinyo Gakkai Zasshi*, 93:539-547, 2002.
26. Buck, A.C., Rees, R.W.M., and Ebeling, L., "Treatment of Chronic Prostatitis and Prostatodynia with Pollen Extract", *Br J Urol* 64:496-499, 1989.
27. Jodai, A., Maruta, N., Shimomae, E., et al, "A long-term therapeutic experience with Cernilton in chronic prostatitis", *Hinyo Kiyo* 34:561-568, 1988.
28. Rugendorff, E. W., Weidner, W., Ebeling, L., and Buck, A.C., "Results of Treatment with Pollen Extract (Cernilton®) in Prostatodynia and Chronic Prostatitis", *Br J Urol*, 71:433-438, 1993.
29. Preuss, H.G., Marcusen, C., Regan, J., et al, "Randomized trial of a combination of natural products (cernitin, saw palmetto, B-sitosteriol, vitamin E) on symptoms of benign prostatic hyperplasia (BPH)", *Int. U. and Neph.*, 33:217-225, 2001.
30. Sultan, C., "Inhibition of androgen metabolism and binding by a liposterolic extract of *Serenoa repens* B" in human foreskin fibroblasts". *J. Steroid Biochem* 20:515-519, 1984.
31. Aoki, A., Naito, K., Hashimoto, O., et al., "Clinical evaluation of the effect of tamsulosin hydrochloride and cernitin pollen extract on urinary disturbance associated with benign prostatic hyperplasia in a multicentered study", *Hinyo Kiyo*, 48:259-267, 2002.



## Effects of Cernitin™ pollen extract (CN-009) on the isolated bladder smooth muscles and the intravesical pressure

**Onodera S, Yoshinaga M, Takenaga K, Toyoshima A, Uchiyama T**

Cernitin™ pollen extract (CN-009), extract from several pollen species, has been used for urinary dysfunction. As its mode of action has not been clarified, we investigated the action of CN-009 on the isolated bladder smooth muscles of rats, guinea pigs and cats and the intravesical pressure in female rats. CN-009 contracted isolated detrusor muscles of rats, guinea pigs and cats in a concentration-dependent manner. In the guinea pig detrusor muscle, the contractile effect of CN-009 was depressed by atropine, diphenhydramine and increased by cimetidine. In the rat detrusor muscle, the CN-009-induced contraction was depressed by atropine. In adult rats (11-23 weeks old) and aged rats (2 years old), CN-009 showed a dose-dependent increase of intravesical pressure to the same extent in spite of the fact that the aged rats had a lower responsiveness to acetylcholine. In adult rats, the CN-009-induced increase of intravesical pressure was reduced completely by atropine and partly reduced by phentolamine and guanethidine. Three weeks consecutive oral administration of CN-009 tended to increase the basal intravesical pressure and tended to elevate the isoproterenol-induced decrease and serotonin-induced increase in the intravesical pressure. These results suggest that CN-009 contracts the detrusor muscle, a process that is mainly mediated by muscarinic receptor activation. The contraction induced by CN-009 of detrusor muscle causes the increase of intravesical pressure.

PMID: 1879805, UI: 91348658

Department of Pharmacology  
Toho University School of Medicine  
Tokyo, Japan

### Inhibitory effect and synergism of Cernitin™ pollen extract on the urethral smooth muscle and diaphragm of the rat

**Nakase K, Takenaga K, Hamanaka T, Kimura M**

Inhibitory effects of Cernitin™ pollen extract (CN-009), consisting of T-60 (a water-soluble extract) and GBX (an acetone-soluble extract) at a ratio of 20:1, were investigated in rat urethral smooth muscle and diaphragm. In the urethral smooth muscle, CN-009 ( $3.0 \times 10^{-4}$ ) approximately  $3.0 \times 10^{-3}$  g/ml, T-60 and GBX (corresponding to CN-009) concentration-dependently inhibited the noradrenaline (NA,  $10^{-5}$  g/ml)-induced contraction. According to Burgi's calculation, the inhibition by T-60 and GBX was synergistic. On the other hand, GBX inhibited the NA-contraction non-competitively and also inhibited the K<sup>+</sup>-contraction. In contrast, T-60 tended to inhibit competitively, but did not affect the K<sup>+</sup>-contraction. In the diaphragm, CN-009 ( $5.25 \times 10^{-3}$ ) approximately  $2.1 \times 10^{-2}$  g/ml concentration-dependently inhibited the nerve stimulation-induced twitch response. T-60 (corresponding to CN-009) showed no effect, while GBX slightly inhibited the twitch response. The effects of T-60 and GBX were synergistic. The inhibitory effects of CN-009 ( $2.1 \times 10^{-2}$  g/ml) and GBX ( $1.0 \times 10^{-2}$  g/ml) were specific against the nerve stimulation and were not antagonized by neostigmine ( $1.0 \times 10^{-5}$  g/ml). These results suggested that these effects were neither musculotropic nor competitive against ACh. In conclusion, CN-009 concentration-dependently inhibited the urethral contraction and the skeletal muscular twitch response. It was suggested that T-60 and GBX had different mechanisms and inhibited the response synergistically.

PMID: 3417212, UI: 88329868

Ome Research Laboratories  
Tobishi Pharmaceutical Co., Ltd.  
Tokyo, Japan.

*Nippon Yakurigaku Zasshi* 1988 Jun;91(6):385-92